Global Transthyretin Amyloidosis Drug Market Research Report 2023

Transthyretin Amyloidosis Drug Market

Transthyretin amyloidosis is a slowly progressive disease in which abnormal deposits of a protein called amyloid occur in the body's organs and tissues of the person. It is a progressive and fatal rare disease that can destroy nerve cells. It is often considered difficult to recognize and diagnose properly, and treatment is generally critical. However, the most common symptoms include heart failure, chronic diarrhea, weight loss, dry mouth, constipation, carpal tunnel syndrome, impaired kidney function, and floaters.

Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Transthyretin Amyloidosis Drug market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Transthyretin Amyloidosis Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Transthyretin Amyloidosis Drug Market Report

1.1 Product Overview and Scope of Transthyretin Amyloidosis Drug

1.2 Transthyretin Amyloidosis Drug Segment by Type

1.2.1 Global Transthyretin Amyloidosis Drug Market Value Comparison by Type (2023-2029)

1.2.2 Tafamidis

1.2.3 Patisiran

1.2.4 Inotersen

1.2.5 Other

1.3 Transthyretin Amyloidosis Drug Segment by Application

1.3.1 Global Transthyretin Amyloidosis Drug Market Value by Application: (2023-2029)

1.3.2 Hereditary Transthyretin Amyloidosis

1.3.3 Wild Transthyretin Amyloidosis

1.4 Global Transthyretin Amyloidosis Drug Market Size Estimates and Forecasts

1.4.1 Global Transthyretin Amyloidosis Drug Revenue 2018-2029

1.4.2 Global Transthyretin Amyloidosis Drug Sales 2018-2029

1.4.3 Global Transthyretin Amyloidosis Drug Market Average Price (2018-2029)

1.5 Assumptions and Limitations

2.1 Global Transthyretin Amyloidosis Drug Sales Market Share by Manufacturers (2018-2023)

2.2 Global Transthyretin Amyloidosis Drug Revenue Market Share by Manufacturers (2018-2023)

2.3 Global Transthyretin Amyloidosis Drug Average Price by Manufacturers (2018-2023)

2.4 Global Transthyretin Amyloidosis Drug Industry Ranking 2021 VS 2022 VS 2023

2.5 Global Key Manufacturers of Transthyretin Amyloidosis Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Transthyretin Amyloidosis Drug, Product Type & Application

2.7 Transthyretin Amyloidosis Drug Market Competitive Situation and Trends

2.7.1 Transthyretin Amyloidosis Drug Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Transthyretin Amyloidosis Drug Players Market Share by Revenue

2.7.3 Global Transthyretin Amyloidosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Transthyretin Amyloidosis Drug Market Size by Region: 2018 Versus 2022 Versus 2029

3.2 Global Transthyretin Amyloidosis Drug Global Transthyretin Amyloidosis Drug Sales by Region: 2018-2029

3.2.1 Global Transthyretin Amyloidosis Drug Sales by Region: 2018-2023

3.2.2 Global Transthyretin Amyloidosis Drug Sales by Region: 2024-2029

3.3 Global Transthyretin Amyloidosis Drug Global Transthyretin Amyloidosis Drug Revenue by Region: 2018-2029

3.3.1 Global Transthyretin Amyloidosis Drug Revenue by Region: 2018-2023

3.3.2 Global Transthyretin Amyloidosis Drug Revenue by Region: 2024-2029

3.4 North America Transthyretin Amyloidosis Drug Market Facts & Figures by Country

3.4.1 North America Transthyretin Amyloidosis Drug Market Size by Country: 2018 VS 2022 VS 2029

3.4.2 North America Transthyretin Amyloidosis Drug Sales by Country (2018-2029)

3.4.3 North America Transthyretin Amyloidosis Drug Revenue by Country (2018-2029)

3.4.4 United States

3.4.5 Canada

3.5 Europe Transthyretin Amyloidosis Drug Market Facts & Figures by Country

3.5.1 Europe Transthyretin Amyloidosis Drug Market Size by Country: 2018 VS 2022 VS 2029

3.5.2 Europe Transthyretin Amyloidosis Drug Sales by Country (2018-2029)

3.5.3 Europe Transthyretin Amyloidosis Drug Revenue by Country (2018-2029)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Transthyretin Amyloidosis Drug Market Facts & Figures by Country

3.6.1 Asia Pacific Transthyretin Amyloidosis Drug Market Size by Country: 2018 VS 2022 VS 2029

3.6.2 Asia Pacific Transthyretin Amyloidosis Drug Sales by Country (2018-2029)

3.6.3 Asia Pacific Transthyretin Amyloidosis Drug Revenue by Country (2018-2029)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Transthyretin Amyloidosis Drug Market Facts & Figures by Country

3.7.1 Latin America Transthyretin Amyloidosis Drug Market Size by Country: 2018 VS 2022 VS 2029

3.7.2 Latin America Transthyretin Amyloidosis Drug Sales by Country (2018-2029)

3.7.3 Latin America Transthyretin Amyloidosis Drug Revenue by Country (2018-2029)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Transthyretin Amyloidosis Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Transthyretin Amyloidosis Drug Market Size by Country: 2018 VS 2022 VS 2029

3.8.2 Middle East and Africa Transthyretin Amyloidosis Drug Sales by Country (2018-2029)

3.8.3 Middle East and Africa Transthyretin Amyloidosis Drug Revenue by Country (2018-2029)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4.1 Global Transthyretin Amyloidosis Drug Sales by Type (2018-2029)

4.1.1 Global Transthyretin Amyloidosis Drug Sales by Type (2018-2023)

4.1.2 Global Transthyretin Amyloidosis Drug Sales by Type (2024-2029)

4.1.3 Global Transthyretin Amyloidosis Drug Sales Market Share by Type (2018-2029)

4.2 Global Transthyretin Amyloidosis Drug Revenue by Type (2018-2029)

4.2.1 Global Transthyretin Amyloidosis Drug Revenue by Type (2018-2023)

4.2.2 Global Transthyretin Amyloidosis Drug Revenue by Type (2024-2029)

4.2.3 Global Transthyretin Amyloidosis Drug Revenue Market Share by Type (2018-2029)

4.3 Global Transthyretin Amyloidosis Drug Price by Type (2018-2029)

5.1 Global Transthyretin Amyloidosis Drug Sales by Application (2018-2029)

5.1.1 Global Transthyretin Amyloidosis Drug Sales by Application (2018-2023)

5.1.2 Global Transthyretin Amyloidosis Drug Sales by Application (2024-2029)

5.1.3 Global Transthyretin Amyloidosis Drug Sales Market Share by Application (2018-2029)

5.2 Global Transthyretin Amyloidosis Drug Revenue by Application (2018-2029)

5.2.1 Global Transthyretin Amyloidosis Drug Revenue by Application (2018-2023)

5.2.2 Global Transthyretin Amyloidosis Drug Revenue by Application (2024-2029)

5.2.3 Global Transthyretin Amyloidosis Drug Revenue Market Share by Application (2018-2029)

5.3 Global Transthyretin Amyloidosis Drug Price by Application (2018-2029)

6.1 Pfizer Inc

6.1.1 Pfizer Inc Corporation Information

6.1.2 Pfizer Inc Description and Business Overview

6.1.3 Pfizer Inc Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.1.4 Pfizer Inc Transthyretin Amyloidosis Drug Product Portfolio

6.1.5 Pfizer Inc Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Corporation Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.2.4 AstraZeneca Transthyretin Amyloidosis Drug Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Prothena Corporation plc

6.3.1 Prothena Corporation plc Corporation Information

6.3.2 Prothena Corporation plc Description and Business Overview

6.3.3 Prothena Corporation plc Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.3.4 Prothena Corporation plc Transthyretin Amyloidosis Drug Product Portfolio

6.3.5 Prothena Corporation plc Recent Developments/Updates

6.4 Ionis Pharmaceuticals

6.4.1 Ionis Pharmaceuticals Corporation Information

6.4.2 Ionis Pharmaceuticals Description and Business Overview

6.4.3 Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Product Portfolio

6.4.5 Ionis Pharmaceuticals Recent Developments/Updates

6.5 BELLUS Health Inc

6.5.1 BELLUS Health Inc Corporation Information

6.5.2 BELLUS Health Inc Description and Business Overview

6.5.3 BELLUS Health Inc Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.5.4 BELLUS Health Inc Transthyretin Amyloidosis Drug Product Portfolio

6.5.5 BELLUS Health Inc Recent Developments/Updates

6.6 Alnylam Pharmaceuticals, Inc

6.6.1 Alnylam Pharmaceuticals, Inc Corporation Information

6.6.2 Alnylam Pharmaceuticals, Inc Description and Business Overview

6.6.3 Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.6.4 Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Product Portfolio

6.6.5 Alnylam Pharmaceuticals, Inc Recent Developments/Updates

6.7 Eidos Therapeutics, Inc

6.6.1 Eidos Therapeutics, Inc Corporation Information

6.6.2 Eidos Therapeutics, Inc Description and Business Overview

6.6.3 Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Product Portfolio

6.7.5 Eidos Therapeutics, Inc Recent Developments/Updates

6.8 SOM BIOTECH

6.8.1 SOM BIOTECH Corporation Information

6.8.2 SOM BIOTECH Description and Business Overview

6.8.3 SOM BIOTECH Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.8.4 SOM BIOTECH Transthyretin Amyloidosis Drug Product Portfolio

6.8.5 SOM BIOTECH Recent Developments/Updates

6.9 Abbvie, Inc

6.9.1 Abbvie, Inc Corporation Information

6.9.2 Abbvie, Inc Description and Business Overview

6.9.3 Abbvie, Inc Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.9.4 Abbvie, Inc Transthyretin Amyloidosis Drug Product Portfolio

6.9.5 Abbvie, Inc Recent Developments/Updates

6.10 Bausch Health Companies Inc

6.10.1 Bausch Health Companies Inc Corporation Information

6.10.2 Bausch Health Companies Inc Description and Business Overview

6.10.3 Bausch Health Companies Inc Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.10.4 Bausch Health Companies Inc Transthyretin Amyloidosis Drug Product Portfolio

6.10.5 Bausch Health Companies Inc Recent Developments/Updates

6.11 Bristol Myers Squibb Company

6.11.1 Bristol Myers Squibb Company Corporation Information

6.11.2 Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Description and Business Overview

6.11.3 Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.11.4 Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Product Portfolio

6.11.5 Bristol Myers Squibb Company Recent Developments/Updates

6.12 GSK Plc

6.12.1 GSK Plc Corporation Information

6.12.2 GSK Plc Transthyretin Amyloidosis Drug Description and Business Overview

6.12.3 GSK Plc Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.12.4 GSK Plc Transthyretin Amyloidosis Drug Product Portfolio

6.12.5 GSK Plc Recent Developments/Updates

6.13 Merck KGaA

6.13.1 Merck KGaA Corporation Information

6.13.2 Merck KGaA Transthyretin Amyloidosis Drug Description and Business Overview

6.13.3 Merck KGaA Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.13.4 Merck KGaA Transthyretin Amyloidosis Drug Product Portfolio

6.13.5 Merck KGaA Recent Developments/Updates

6.14 Sanofi

6.14.1 Sanofi Corporation Information

6.14.2 Sanofi Transthyretin Amyloidosis Drug Description and Business Overview

6.14.3 Sanofi Transthyretin Amyloidosis Drug Sales, Revenue and Gross Margin (2018-2023)

6.14.4 Sanofi Transthyretin Amyloidosis Drug Product Portfolio

6.14.5 Sanofi Recent Developments/Updates

7.1 Transthyretin Amyloidosis Drug Industry Chain Analysis

7.2 Transthyretin Amyloidosis Drug Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Transthyretin Amyloidosis Drug Production Mode & Process

7.4 Transthyretin Amyloidosis Drug Sales and Marketing

7.4.1 Transthyretin Amyloidosis Drug Sales Channels

7.4.2 Transthyretin Amyloidosis Drug Distributors

7.5 Transthyretin Amyloidosis Drug Customers

8.1 Transthyretin Amyloidosis Drug Industry Trends

8.2 Transthyretin Amyloidosis Drug Market Drivers

8.3 Transthyretin Amyloidosis Drug Market Challenges

8.4 Transthyretin Amyloidosis Drug Market Restraints

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

    Table 1. Global Transthyretin Amyloidosis Drug Market Value Comparison by Type (2023-2029) & (US$ Million)

    Table 2. Global Transthyretin Amyloidosis Drug Market Value Comparison by Application (2023-2029) & (US$ Million)

    Table 3. Global Transthyretin Amyloidosis Drug Market Competitive Situation by Manufacturers in 2022

    Table 4. Global Transthyretin Amyloidosis Drug Sales (K Units) of Key Manufacturers (2018-2023)

    Table 5. Global Transthyretin Amyloidosis Drug Sales Market Share by Manufacturers (2018-2023)

    Table 6. Global Transthyretin Amyloidosis Drug Revenue (US$ Million) by Manufacturers (2018-2023)

    Table 7. Global Transthyretin Amyloidosis Drug Revenue Share by Manufacturers (2018-2023)

    Table 8. Global Market Transthyretin Amyloidosis Drug Average Price (US$/Unit) of Key Manufacturers (2018-2023)

    Table 9. Global Key Players of Transthyretin Amyloidosis Drug, Industry Ranking, 2021 VS 2022 VS 2023

    Table 10. Global Key Manufacturers of Transthyretin Amyloidosis Drug, Manufacturing Sites & Headquarters

    Table 11. Global Key Manufacturers of Transthyretin Amyloidosis Drug, Product Type & Application

    Table 12. Global Key Manufacturers of Transthyretin Amyloidosis Drug, Date of Enter into This Industry

    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

    Table 14. Global Transthyretin Amyloidosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin Amyloidosis Drug as of 2022)

    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

    Table 16. Global Transthyretin Amyloidosis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 17. Global Transthyretin Amyloidosis Drug Sales by Region (2018-2023) & (K Units)

    Table 18. Global Transthyretin Amyloidosis Drug Sales Market Share by Region (2018-2023)

    Table 19. Global Transthyretin Amyloidosis Drug Sales by Region (2024-2029) & (K Units)

    Table 20. Global Transthyretin Amyloidosis Drug Sales Market Share by Region (2024-2029)

    Table 21. Global Transthyretin Amyloidosis Drug Revenue by Region (2018-2023) & (US$ Million)

    Table 22. Global Transthyretin Amyloidosis Drug Revenue Market Share by Region (2018-2023)

    Table 23. Global Transthyretin Amyloidosis Drug Revenue by Region (2024-2029) & (US$ Million)

    Table 24. Global Transthyretin Amyloidosis Drug Revenue Market Share by Region (2024-2029)

    Table 25. North America Transthyretin Amyloidosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 26. North America Transthyretin Amyloidosis Drug Sales by Country (2018-2023) & (K Units)

    Table 27. North America Transthyretin Amyloidosis Drug Sales by Country (2024-2029) & (K Units)

    Table 28. North America Transthyretin Amyloidosis Drug Revenue by Country (2018-2023) & (US$ Million)

    Table 29. North America Transthyretin Amyloidosis Drug Revenue by Country (2024-2029) & (US$ Million)

    Table 30. Europe Transthyretin Amyloidosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 31. Europe Transthyretin Amyloidosis Drug Sales by Country (2018-2023) & (K Units)

    Table 32. Europe Transthyretin Amyloidosis Drug Sales by Country (2024-2029) & (K Units)

    Table 33. Europe Transthyretin Amyloidosis Drug Revenue by Country (2018-2023) & (US$ Million)

    Table 34. Europe Transthyretin Amyloidosis Drug Revenue by Country (2024-2029) & (US$ Million)

    Table 35. Asia Pacific Transthyretin Amyloidosis Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)

    Table 36. Asia Pacific Transthyretin Amyloidosis Drug Sales by Region (2018-2023) & (K Units)

    Table 37. Asia Pacific Transthyretin Amyloidosis Drug Sales by Region (2024-2029) & (K Units)

    Table 38. Asia Pacific Transthyretin Amyloidosis Drug Revenue by Region (2018-2023) & (US$ Million)

    Table 39. Asia Pacific Transthyretin Amyloidosis Drug Revenue by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Transthyretin Amyloidosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 41. Latin America Transthyretin Amyloidosis Drug Sales by Country (2018-2023) & (K Units)

    Table 42. Latin America Transthyretin Amyloidosis Drug Sales by Country (2024-2029) & (K Units)

    Table 43. Latin America Transthyretin Amyloidosis Drug Revenue by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Transthyretin Amyloidosis Drug Revenue by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Transthyretin Amyloidosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 46. Middle East & Africa Transthyretin Amyloidosis Drug Sales by Country (2018-2023) & (K Units)

    Table 47. Middle East & Africa Transthyretin Amyloidosis Drug Sales by Country (2024-2029) & (K Units)

    Table 48. Middle East & Africa Transthyretin Amyloidosis Drug Revenue by Country (2018-2023) & (US$ Million)

    Table 49. Middle East & Africa Transthyretin Amyloidosis Drug Revenue by Country (2024-2029) & (US$ Million)

    Table 50. Global Transthyretin Amyloidosis Drug Sales (K Units) by Type (2018-2023)

    Table 51. Global Transthyretin Amyloidosis Drug Sales (K Units) by Type (2024-2029)

    Table 52. Global Transthyretin Amyloidosis Drug Sales Market Share by Type (2018-2023)

    Table 53. Global Transthyretin Amyloidosis Drug Sales Market Share by Type (2024-2029)

    Table 54. Global Transthyretin Amyloidosis Drug Revenue (US$ Million) by Type (2018-2023)

    Table 55. Global Transthyretin Amyloidosis Drug Revenue (US$ Million) by Type (2024-2029)

    Table 56. Global Transthyretin Amyloidosis Drug Revenue Market Share by Type (2018-2023)

    Table 57. Global Transthyretin Amyloidosis Drug Revenue Market Share by Type (2024-2029)

    Table 58. Global Transthyretin Amyloidosis Drug Price (US$/Unit) by Type (2018-2023)

    Table 59. Global Transthyretin Amyloidosis Drug Price (US$/Unit) by Type (2024-2029)

    Table 60. Global Transthyretin Amyloidosis Drug Sales (K Units) by Application (2018-2023)

    Table 61. Global Transthyretin Amyloidosis Drug Sales (K Units) by Application (2024-2029)

    Table 62. Global Transthyretin Amyloidosis Drug Sales Market Share by Application (2018-2023)

    Table 63. Global Transthyretin Amyloidosis Drug Sales Market Share by Application (2024-2029)

    Table 64. Global Transthyretin Amyloidosis Drug Revenue (US$ Million) by Application (2018-2023)

    Table 65. Global Transthyretin Amyloidosis Drug Revenue (US$ Million) by Application (2024-2029)

    Table 66. Global Transthyretin Amyloidosis Drug Revenue Market Share by Application (2018-2023)

    Table 67. Global Transthyretin Amyloidosis Drug Revenue Market Share by Application (2024-2029)

    Table 68. Global Transthyretin Amyloidosis Drug Price (US$/Unit) by Application (2018-2023)

    Table 69. Global Transthyretin Amyloidosis Drug Price (US$/Unit) by Application (2024-2029)

    Table 70. Pfizer Inc Corporation Information

    Table 71. Pfizer Inc Description and Business Overview

    Table 72. Pfizer Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 73. Pfizer Inc Transthyretin Amyloidosis Drug Product

    Table 74. Pfizer Inc Recent Developments/Updates

    Table 75. AstraZeneca Corporation Information

    Table 76. AstraZeneca Description and Business Overview

    Table 77. AstraZeneca Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 78. AstraZeneca Transthyretin Amyloidosis Drug Product

    Table 79. AstraZeneca Recent Developments/Updates

    Table 80. Prothena Corporation plc Corporation Information

    Table 81. Prothena Corporation plc Description and Business Overview

    Table 82. Prothena Corporation plc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 83. Prothena Corporation plc Transthyretin Amyloidosis Drug Product

    Table 84. Prothena Corporation plc Recent Developments/Updates

    Table 85. Ionis Pharmaceuticals Corporation Information

    Table 86. Ionis Pharmaceuticals Description and Business Overview

    Table 87. Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 88. Ionis Pharmaceuticals Transthyretin Amyloidosis Drug Product

    Table 89. Ionis Pharmaceuticals Recent Developments/Updates

    Table 90. BELLUS Health Inc Corporation Information

    Table 91. BELLUS Health Inc Description and Business Overview

    Table 92. BELLUS Health Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 93. BELLUS Health Inc Transthyretin Amyloidosis Drug Product

    Table 94. BELLUS Health Inc Recent Developments/Updates

    Table 95. Alnylam Pharmaceuticals, Inc Corporation Information

    Table 96. Alnylam Pharmaceuticals, Inc Description and Business Overview

    Table 97. Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 98. Alnylam Pharmaceuticals, Inc Transthyretin Amyloidosis Drug Product

    Table 99. Alnylam Pharmaceuticals, Inc Recent Developments/Updates

    Table 100. Eidos Therapeutics, Inc Corporation Information

    Table 101. Eidos Therapeutics, Inc Description and Business Overview

    Table 102. Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 103. Eidos Therapeutics, Inc Transthyretin Amyloidosis Drug Product

    Table 104. Eidos Therapeutics, Inc Recent Developments/Updates

    Table 105. SOM BIOTECH Corporation Information

    Table 106. SOM BIOTECH Description and Business Overview

    Table 107. SOM BIOTECH Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 108. SOM BIOTECH Transthyretin Amyloidosis Drug Product

    Table 109. SOM BIOTECH Recent Developments/Updates

    Table 110. Abbvie, Inc Corporation Information

    Table 111. Abbvie, Inc Description and Business Overview

    Table 112. Abbvie, Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 113. Abbvie, Inc Transthyretin Amyloidosis Drug Product

    Table 114. Abbvie, Inc Recent Developments/Updates

    Table 115. Bausch Health Companies Inc Corporation Information

    Table 116. Bausch Health Companies Inc Description and Business Overview

    Table 117. Bausch Health Companies Inc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 118. Bausch Health Companies Inc Transthyretin Amyloidosis Drug Product

    Table 119. Bausch Health Companies Inc Recent Developments/Updates

    Table 120. Bristol Myers Squibb Company Corporation Information

    Table 121. Bristol Myers Squibb Company Description and Business Overview

    Table 122. Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 123. Bristol Myers Squibb Company Transthyretin Amyloidosis Drug Product

    Table 124. Bristol Myers Squibb Company Recent Developments/Updates

    Table 125. GSK Plc Corporation Information

    Table 126. GSK Plc Description and Business Overview

    Table 127. GSK Plc Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 128. GSK Plc Transthyretin Amyloidosis Drug Product

    Table 129. GSK Plc Recent Developments/Updates

    Table 130. Merck KGaA Corporation Information

    Table 131. Merck KGaA Description and Business Overview

    Table 132. Merck KGaA Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 133. Merck KGaA Transthyretin Amyloidosis Drug Product

    Table 134. Merck KGaA Recent Developments/Updates

    Table 135. Sanofi Corporation Information

    Table 136. Sanofi Description and Business Overview

    Table 137. Sanofi Transthyretin Amyloidosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 138. Sanofi Transthyretin Amyloidosis Drug Product

    Table 139. Sanofi Recent Developments/Updates

    Table 140. Key Raw Materials Lists

    Table 141. Raw Materials Key Suppliers Lists

    Table 142. Transthyretin Amyloidosis Drug Distributors List

    Table 143. Transthyretin Amyloidosis Drug Customers List

    Table 144. Transthyretin Amyloidosis Drug Market Trends

    Table 145. Transthyretin Amyloidosis Drug Market Drivers

    Table 146. Transthyretin Amyloidosis Drug Market Challenges

    Table 147. Transthyretin Amyloidosis Drug Market Restraints

    Table 148. Research Programs/Design for This Report

    Table 149. Key Data Information from Secondary Sources

    Table 150. Key Data Information from Primary Sources

List of Figures

    Figure 1. Product Picture of Transthyretin Amyloidosis Drug

    Figure 2. Global Transthyretin Amyloidosis Drug Market Value Comparison by Type (2023-2029) & (US$ Million)

    Figure 3. Global Transthyretin Amyloidosis Drug Market Share by Type in 2022 & 2029

    Figure 4. Tafamidis Product Picture

    Figure 5. Patisiran Product Picture

    Figure 6. Inotersen Product Picture

    Figure 7. Other Product Picture

    Figure 8. Global Transthyretin Amyloidosis Drug Market Value Comparison by Application (2023-2029) & (US$ Million)

    Figure 9. Global Transthyretin Amyloidosis Drug Market Share by Application in 2022 & 2029

    Figure 10. Hereditary Transthyretin Amyloidosis

    Figure 11. Wild Transthyretin Amyloidosis

    Figure 12. Global Transthyretin Amyloidosis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029

    Figure 13. Global Transthyretin Amyloidosis Drug Market Size (2018-2029) & (US$ Million)

    Figure 14. Global Transthyretin Amyloidosis Drug Sales (2018-2029) & (K Units)

    Figure 15. Global Transthyretin Amyloidosis Drug Average Price (US$/Unit) & (2018-2029)

    Figure 16. Transthyretin Amyloidosis Drug Report Years Considered

    Figure 17. Transthyretin Amyloidosis Drug Sales Share by Manufacturers in 2022

    Figure 18. Global Transthyretin Amyloidosis Drug Revenue Share by Manufacturers in 2022

    Figure 19. The Global 5 and 10 Largest Transthyretin Amyloidosis Drug Players: Market Share by Revenue in 2022

    Figure 20. Transthyretin Amyloidosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

    Figure 21. Global Transthyretin Amyloidosis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Figure 22. North America Transthyretin Amyloidosis Drug Sales Market Share by Country (2018-2029)

    Figure 23. North America Transthyretin Amyloidosis Drug Revenue Market Share by Country (2018-2029)

    Figure 24. United States Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 25. Canada Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 26. Europe Transthyretin Amyloidosis Drug Sales Market Share by Country (2018-2029)

    Figure 27. Europe Transthyretin Amyloidosis Drug Revenue Market Share by Country (2018-2029)

    Figure 28. Germany Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 29. France Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 30. U.K. Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 31. Italy Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 32. Russia Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 33. Asia Pacific Transthyretin Amyloidosis Drug Sales Market Share by Region (2018-2029)

    Figure 34. Asia Pacific Transthyretin Amyloidosis Drug Revenue Market Share by Region (2018-2029)

    Figure 35. China Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 36. Japan Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 37. South Korea Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 38. India Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 39. Australia Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 40. China Taiwan Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 41. Southeast Asia Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 42. Latin America Transthyretin Amyloidosis Drug Sales Market Share by Country (2018-2029)

    Figure 43. Latin America Transthyretin Amyloidosis Drug Revenue Market Share by Country (2018-2029)

    Figure 44. Mexico Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 45. Brazil Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 46. Argentina Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 47. Middle East & Africa Transthyretin Amyloidosis Drug Sales Market Share by Country (2018-2029)

    Figure 48. Middle East & Africa Transthyretin Amyloidosis Drug Revenue Market Share by Country (2018-2029)

    Figure 49. Turkey Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 50. Saudi Arabia Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 51. UAE Transthyretin Amyloidosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 52. Global Sales Market Share of Transthyretin Amyloidosis Drug by Type (2018-2029)

    Figure 53. Global Revenue Market Share of Transthyretin Amyloidosis Drug by Type (2018-2029)

    Figure 54. Global Transthyretin Amyloidosis Drug Price (US$/Unit) by Type (2018-2029)

    Figure 55. Global Sales Market Share of Transthyretin Amyloidosis Drug by Application (2018-2029)

    Figure 56. Global Revenue Market Share of Transthyretin Amyloidosis Drug by Application (2018-2029)

    Figure 57. Global Transthyretin Amyloidosis Drug Price (US$/Unit) by Application (2018-2029)

    Figure 58. Transthyretin Amyloidosis Drug Value Chain

    Figure 59. Transthyretin Amyloidosis Drug Production Process

    Figure 60. Channels of Distribution (Direct Vs Distribution)

    Figure 61. Distributors Profiles

    Figure 62. Bottom-up and Top-down Approaches for This Report

    Figure 63. Data Triangulation

    Figure 64. Key Executives Interviewed